

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02607)

CHANGE OF JOINT COMPANY SECRETARY AND AGENT FOR THE ACCEPTANCE OF SERVICE OF PROCESS AND NOTICES IN HONG KONG

The board of directors (the “**Board**”) of Shanghai Pharmaceuticals Holding Co., Ltd. (the “**Company**”) hereby announces that Ms. LEUNG Suet Wing (梁雪穎) has resigned as one of the joint company secretaries and the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) due to work re-allocation, all with effect from 23 July 2021. Ms. LEUNG Suet Wing has confirmed that there is no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company in relation to her resignation.

The Board is pleased to further announce that Ms. LEUNG Shui Bing (梁瑞冰) has been appointed as one of the joint company secretaries of the Company and the Process Agent, with effect from 23 July 2021. Ms. Chen Jinzhu (陳津竹) (“**Ms. Chen**”) will continue to serve as the other joint company secretary of the Company.

Ms. LEUNG Shui Bing is a manager of the Listing Services Department of TMF Hong Kong Limited. Ms. LEUNG Shui Bing has over 15 years of professional experience in the company secretarial field. She is a member of the Hong Kong Institute of Chartered Secretaries and the Chartered Governance Institute in the United Kingdom.

The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) has granted a waiver to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), for a period from 23 July 2021 to 28 August 2022 (the “**New Waiver Period**”) in relation to Ms. Chen’s eligibility to act as the joint company secretary of the Company on the condition that (i) Ms. Chen will be assisted by Ms. LEUNG Shui Bing during the New Waiver Period; and (ii) this Waiver could be revoked if there are material breaches of the Listing Rules

by the Company. The Stock Exchange may withdraw or change the Waiver if the Company's situation changes. Before the end of the New Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Ms. Chen, having had the benefit of Ms. LEUNG Shui Bing's assistance during the New Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary

The Board would like to take this opportunity to express its sincere gratitude to Ms. LEUNG Suet Wing for her invaluable contribution to the Company during his tenure of services, and to express its welcome to Ms. LEUNG Shui Bing on her new appointment.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
ZHOU Jun
Chairman

Shanghai, the PRC, 24 July 2021

As at the date of this announcement, the executive Directors of the Company are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo; the non-executive Directors are Mr. ZHOU Jun, Mr. GE Dawei and Ms. LI An; and the independent non-executive Directors are Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK.

** For identification purpose only*